Abstract
Inflammatory bowel disease (IBD) is a group of inflammatory conditions of both the large and small intestine. The major types of IBD are Crohn’s disease (CD) and ulcerative colitis (UC). CD is also known as granulomatous colitis, regional enteritis, and i leitis. It is an inflammatory disease that may affect any part of the gastrointestinal tract from the mouth to the anus, causing a wide variety of symptoms. Because the symptoms of CD are similar to other intestinal disorders, such as irritable bowel syndrome and UC, it can be difficult to diagnose. In CD, all layers of the intestine may be involved, and normal healthy bowel can be found between sections of diseased bowel.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Schreiber S, Rosenstiel P, Albrecht M et al (2005) Genetics of Crohn disease, an archetypal inflammatory barrier disease. Nat Rev Genet 6(5):376–388
Sartor RB (2006) Mechanisms of disease: Pathogenesis of Crohn’s disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 3(7):390–407
Eaden JA, Abrams KR, Mayberry JF (2001) The risk of colorectal cancer in ulcerative colitis: A meta-analysis. Gut 48(4):526–535
van Staa TP, Card T, Logan RF et al (2005) 5-Aminosalicylate us and colorectal risk in inflammatory bowel disease: A large epidemiological study. Gut 54(11):1573–1578
Baumgart DC, Sandborn WJ (2007) Inflammatory bowel disease: Clinical aspects and established and evolving therapies. Lancet 369:1641–1657
Blomqvist P, Feltelius N, Löfberg R et al (2001) A 10-year survey of inflammatory bowel diseases-drug therapy, costs and adverse reactions. Aliment Pharmacol Ther 15:475–481
Gyde SN, Prior P, Macartney JC et al (1980) Malignancy in Crohn’s disease. Gut 21:1024–1029
Ekbom A, Helmick C, Zack M et al (1990) Increased risk of large-bowel cancer in Crohn’s disease with colonic involvement. Lancet 336:357–359
Canavan D, Abrams KR, Mayberry J (2006) Meta-Analysis colorectal and small bowel cancer risk in patients with Crohn’s disease. Aliment Pharmacol Ther 23:1097–1104
Jess T, Gamborg M, Matzen P et al (2005) Increased risk of intestinal cancer in Crohn’s disease: A meta-analysis of population-based cohort studies. Am J Gastroenterol 100:2724–2729
Gillen CD, Walmsley RS, Prior P et al (1994) Ulcerative colitis and Crohn’s disease: a comparison of the colorectal cancer risk in extensive colitis. Gut 25:1590–1592
Bernstein CN, Blanchard JF, Kliewer E et al (2001) Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 91:854–862
Jess T, Loftus EV Jr, Velayos FS et al (2006) Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Gastroenterology 130:1039–1046
Koga H, Aoyagi K, Hizawa K et al (1999) Rapidly and infiltratively growing Crohn’s carcinoma of the small bowel: serial radiologic findings and a review of the literature. Clin Imaging 23:298–301
Solem CA, Harmsen WS, Zinsmeister AR et al (2004) Small intestinal adenocarcinoma in Crohn’s disease: a case-control study. Inflamm Bowel Dis 10:32–35
Jess T, Winther KV, Munkholm P et al (2004) Intestinal and extra-intestinal cancer in Crohn’s disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Aliment Pharmacol Ther 19:287–293
Barwood N, Platell C (1999) Case report: adenocarcinoma arising in a Crohn’s stricture of the jejunum. J Gastroenterol Hepatol 14:1132–1134
Marchetti F, Faxio VW, Ozuner G (1996) A denocarcinoma arising from a structureplasty site in Crohn’s disease. Report of a case. Dis Colon Rectum 39:1315–1321
Partridge SK, Hodin RA (2004) Small bowel adenocarcinoma at a strictureplasty site in a patient with Crohn’s disease: report of a case. Dis Colon Rectum 47:778–781
Sigel JE, Petras RE, Lashner BA et al (1999) Intestinal adenocarcinoma in Crohn’s disease: a report of 30 cases with a focus on coexisting dysplasia. Am J Surg Pathol 23:651–655
Petras RE, Mir-Madjlessi SH, Farmer RG (1987) Crohn’s disease and intestinal carcinoma. A report of 11 cases with emphasis on associated epithelial dysplasia. Gastroenterology 93:1307–1314
Christodoulou D, Skopelitou AS, Katsanos KH et al (2002) Small bowel adenocarcinoma presenting as a first manifestation of Crohn’s disease: report of a case, and a literature review. Eur J Gastroenterol Hepatol 14:805–810
West NE, Wise PE, Herline AJ et al (2007) Carcinoid tumors are 15 times more common in patients with Crohn’s disease. Inflamm Bowel Dis 13:1129–1134
Gordon, JN, MacDonald TT (2005) Osteopontin: a new addition to the constellation of cytokines which drive T helper cell type 1 responses in Crohn’s disease. Gut 54:1213–1215
Askling J, Dickman PW, Karlén P et al (2001) Family history as risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology 120:1356–1362
Jayaram H, Satsangi J, Chapman RW (2001) Increased colorectal neoplasia in chronic ulcerative colitis complicated by primary sclerosing cholangitis: Fact or fiction? Gut 48:430–434
Xie J, Itzkowitz SH (2008) Cancer in inflammatory bowel disease. World J Gastroenterol 14:378–389
Stahl TJ, Schoetz DJ Jr, Roberts PL et al (1992) Crohn’s disease and carcinoma: increasing justification for surveillance? Dis Colon Rectum 35:850–856
Hamilton SR (1985) Colorectal carcinoma in patients with Crohn’s disease. Gastroenterology 89:398–407
Svrcek M, Cosnes J, Beaugerie L et al (2007) Colorectal neoplasia in Crohn’s colitis: a retrospective comparative study with ulcerative colitis. Histopathology 50:574–583
Itzkowitz SH, Yio X (2004) Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: The role of inflammation. Am J Physiol Gastrointest Liver Physiol 287:G7–17
Sato F, Shibata D, Harpaz N et al (2002) Aberrant methylation of the HPP1 gene in ulcerative colitis-associated colorectal carcinoma. Cancer Res 62:6820–6822
Redston MS, Papadopoulos N, Caldas C et al (1995) Common occurrence of APC and K-ras gene mutations in the spectrum of colitis-associated neoplasias. Gastroenterology 108:383–392
Burmer GC, Rabinovitch PS, Haggitt RC et al (1992) Neoplastic progression in ulcerative colitis: Histology, DNA content, and loss of a p53 allele. Gastroenterology 103:1602–1610
Riddell RH, Goldman H, Ransohoff DF et al (1983) Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 14:931–968
Rubin DT, Rothe JA, Hetzel JT et al (2007) Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? Gastrointest Endosc 65:998–1004
Odze RD, Goldblum J, Noffsinger A et al (2002) Interobserver variability in the diagnosis of ulcerative colitis-associated dysplasia by telepathology. Mod Pathol 15:379–386
Bernstein CN, Shanahan F, Weinstein WM (1994) Are we telling the truth about surveillance colonoscopy in ulcerative colitis? Lancet 343:71–74
Rutter MD, Saunders BP, Wilkinson KH et al (2006) Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 130:1030–1038
Connell WR, Sheffield JP, Kamm MA et al (1994) Lower gastrointestinal malignancy in Crohn’s disease. Gut 35:347–352
Itzkowitz SH, Harpaz N (2004) Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology 126:1634–1648
Friedman S, Rubin PH, Bodian C et al (2008) Screening and surveillance colonoscopy in chronic Crohn’s colitis: results of a surveillance program spanning 25 years. Clin Gastroenterol Hepatol 6:993–998
Itzkowitz SH, Present DH, Crohn’s and Colitis Foundation of America Colon Cancer in IBD Study Group (2005) Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis 11:314–321
Zisman TL, Rubin DT (2008) Colorectal cancer and dysplasia in inflammatory bowel disease. World J Gasroenterol 14:2662–2669
Collins PD, Mpofu C, Watson AJ et al (2006) Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev CD000279
Alos R, Hinojosa J (2008) Timing of surgery in Crohn’s disease: a key issue in the management. World J Gastroenterol 14:5532–5539
Morpurgo E, Petras R, Kimberling J et al (2003) Characterization and clinical behaviour of Crohn’s disease initially presenting predominantly as colitis. Dis Colon Rectum 46:918–924
Gumaste V, Sachar DB, Greenstein AJ (1992) Benign and malignant colorectal strictures in ulcerative colitis. Gut 33:938–941
Velayos FS, Terdiman JP, Walsh JM (2005) Effect of 5-aminosalicylate us on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 100:1345–1353
Bernstein CN, Blanchard JF, Metge C et al (2003) Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? Am J Gastroenterol 98:2784–2788
Zimmerman MJ, Jewell DP (1996) Cytokines and mechanisms of action of glucocorticoids and aminoslaicy lates in the treatment of ulcerative colitis and Crohn’s disease. Aliment Pharmacol Ther 10 (Suppl 2):93–98
Allgayer H (2003) Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther 18 (Suppl 2):10–14
Hasko G, Szabo C, Németh ZH et al (2001) Sulphasalazine inhibits macrophage activation: Inhibitory effects on inducible nitric oxide synthase expression, interleukin-12 production and major histocompatibility complex II expression. Immunology 103:473–478
Greten FR, Eckmann L, Greten TF et al (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118:285–296
Rousseaux C, Lefebvre B, Dubuguoy L et al (2005) Intestinal anti-inflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med 201:1205–1215
Hanauer SB, Feagan BG, Lichtenstein GR (2002) Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359:1541–1549
Sands BE, Anderson FH, Bernstein CN et al (2004) Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 350:876–885
Hanauer SB, Sandborn WJ, Rutgeerts P et al (2006) Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 130:323–333, quiz 591
Sandborn WJ, Feagan BG, Stoinoy S et al (2007) Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med 357:228–238
Bongartz T, Sutton AJ, Sweeting MJ et al (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275–2285
Peyrin-Biroulet L, Deltenre P, De Suray N et al (2008) Efficacy and safety of tumor necrosis factor antogonists in Crohn’s disease: meta-analysis of placebo-controlled trials: Clin Gastroenterol Hepatol 6:644–653
Delaunoit T, Limburg PJ, Goldberg RM et al (2006) Colorectal cancer prognosis among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 4:335–342
Tiersten A, Saltz LB (1996) Influence of inflammatory bowel disease on the ability of patients to tolerate systemic fluorouracil-based chemotherapy. J Clin Oncol 14:2043–2046
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Italia
About this chapter
Cite this chapter
Calabrò, F., Sternberg, C.N. (2010). Crohn’s Disease and Cancer. In: Tersigni, R., Prantera, C. (eds) Crohn’s Disease. Updates in Surgery. Springer, Milano. https://doi.org/10.1007/978-88-470-1472-5_24
Download citation
DOI: https://doi.org/10.1007/978-88-470-1472-5_24
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-1471-8
Online ISBN: 978-88-470-1472-5
eBook Packages: MedicineMedicine (R0)